R. Ortmann Email Address

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology. Our lead drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis (SK), a common non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts. In September 2015, Aclaris acquired a portfolio of oral and topical Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. Aclaris is led by a management team with rich experience and expertise in dermatology and dermatological drug development.